AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Cyber decacorn Wiz in advanced negotiation to acquire Lacework for $150-200 million
2
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
3
The price of failure: Dutch company's chip monopoly born from a bad bet by Intel
4
Google employees arrested following protest over Israel ties at executive’s office
5
Cyber unicorn Armis acquiring Silk Security for $150 million
More news

Biotech

20 stories about Biotech
מייסדי Nucleai

Spatial AI biomarker startup Nucleai raises $14 million led by Merck’s VC arm

03.04.24|CTech
Leveraging AI and machine learning, Nucleai analyzes pathology images and spatial data at the cellular and tissue levels. The proprietary technology extracts detailed patterns and features from medical images, offering insights into the tumor microenvironment, cellular morphology, and spatial relationships between different cell types
ד"ר תומר ברונשטיין סמנכ"ל חדשנות ופיתוח תאגידי בבונוס ביוגרופ

Biotech 2024: Opportunities and challenges for Israeli companies

22.01.24|Tomer Bronshtein
“Despite their strong clinical data and established R&D programs, Israeli biotech companies are undervalued. Following two years of economic downturn, these companies now present attractive investment opportunities,” writes Dr. Tomer Bronshtein, VP for Innovation and Corporate Development at Bonus Biogroup
Ben Rabinowitz Mati Gill

Amiti Ventures joins pharma venture studio AION Labs as a Strategic Partner

08.01.24|James Spiro
The Israeli VC firm joins the Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, BioMed X and Amazon Web Services
Mana.bio founders

Biotech startup Mana.bio raises $19.5 million Seed to accelerate programmable drug delivery

12.10.23|CTech
The company, co-founded by Yogev Debbi, Roy Nevo, Avi Schroeder, and Kira Radinsky, unveiled its AI-based lipid nanoparticle (LNP) delivery platform to accelerate the development of nucleic acid-based therapeutics and vaccines
Scala Biodesign

Scala Biodesign exits stealth with $5.5 million in Seed to engineer future proteins

11.09.23|James Spiro
By fusing physics-based modeling, AI, and biological data analysis, Scala helps companies develop new medicines and foods faster and cheaper than before
IntraGel Founders

Intragel hopes to treat the 10% of inoperable cancer patients

03.08.23|CTech
The company has raised a total of $2 million for its first product, TumoCure, designed for solid tumors found in more than 17 million people.
מוסף שבועי 6.7.23 פרופ' צ'ארלס ברנר

"We won't get eternal life. Scientists who promise it are just selling BS"

16.07.23|Roni Dori
Forget about anti-aging treatments or drinking red wine. Prof. Charles Brenner bursts the balloon inflated by the booming longevity industry, and explains why there is no way to defeat death
Sharon Handelman-Gottlieb Adi eshel

From passion to innovation: Unleashing the power of FemTech in Israel's health landscape

13.06.23|Ariela Karmel
Sharon Handelman-Gotlib's journey to co-founding Shela and the promise of transformative women's health solutions
Environmental responsibility conference CTech Amir Oranim

“Bioplastics can replace any application of traditional fossil-based plastics”

01.05.23|Ariela Karmel
Amir Oranim, CEO and Co-Founder of TripleW, spoke to CTech at the Food Waste and Sustainability conference in Tel Aviv about why converting plastics is the best tool to address food waste
Maya Raya PoLoPo

“We can revolutionize the food industry by offering a sustainable and safer protein source”

09.04.23|CTech
PoLoPo has raised $1.75 million to develop the production of animal-based proteins in plants
ועידת לונדון 2023 פרופ יניב ארליך מנכ"ל Eleven Therapeutics

"We are revolutionizing the world of RNA"

27.03.23|CTech
Yaniv Erlich, CEO of Eleven Therapeutics, was speaking at the Mind the Tech conference in London
צוות Nectin Therapeutics

Nectin Therapeutics raises $25 million Series A to treat advanced cancer tumors

30.11.22|Meir Orbach
The Israeli company is aiming to achieve new standards for efficacy and patient response across a number of difficult-to-treat cancers
Bionaut

Bionaut Labs bags $43 million Series B for micro-robotic drug delivery

28.11.22|CTech
The biotech startup was co-founded by two Israeli robotics entrepreneurs, Michael Shpigelmacher and Aviad Maizels, who previously co-founded PrimeSense, sold to Apple in 2013 for approximately $400 million
מוח Brain Medtech

New treatment aiming to reduce suicidality in Bipolar Disorder

28.11.22|James Spiro
American-Israeli company NRx is currently undergoing a trial that combines two kinds of compounds hoping to reduce the negative side effects of current medicine
Equashield

Biotech company Equashield sells 25% stake to Nordic Capital at $1.3 billion valuation

06.10.22|Golan Hazani
CEO and co-founder Eric Shem-Tov is the largest shareholder at the company, which has registered sales in the hundreds of millions of dollars to hospitals across the world for its manual and automated solutions for the compounding and administration of hazardous drugs
seqentify team

Sequentify raises $7 million to enable larger-scale DNA sequencing

10.05.22|CTech
The biotech startup will supply its next-gen sequencing libraries and software for cancer diagnostics, carrier screening, and Covid-19 monitoring
Yael Porat

BioGenCell raises $16 million Seed round led by Marius Nacht for microvascular diseases treatment

09.05.22|Meir Orbach
The Israeli startup uses stem cells from the patient’s own blood to treat microvascular diseases and is aiming to develop products that may be usable to restore tissues damaged by diabetes, kidney failure, pulmonary hypertension, heart failure, stroke, blindness, and more
מריוס נכט

Marius Nacht: "I won’t have another success in high-tech like Check Point, but in biotech I will"

25.04.22|Meir Orbach and Diana Bahur Nir
Marius Nacht is one of the founding fathers of Israeli cybersecurity, but in recent years he has preferred to invest in biotech. In an exclusive interview with Calcalist, he tells how his interest in the life sciences arose, why it’s important to make long-term investments in Israeli companies, and why he left the digital bank and parted ways with the aMoon fund
Kirill Pevzner and Eran Seger Protai

Protai raises $8 million in Seed for its proteomics-based platform for drug discovery

05.01.22|James Spiro
The company has developed an end-to-end AI-based platform that can map the course of a disease on the protein level
Noam Solomon Immunai

When not knowing is a methodology

05.01.22|Noam Solomon
"When your culture celebrates that knowledge always starts from the lack thereof, people are rewarded for asking the right questions and not just for knowing the answers," writes Noam Solomon, CEO & Co-Founder of Immunai
More Articles